Trevi Therapeutics Inc (TRVI)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Trevi Therapeutics Inc

203-304-2499

195 CHURCH STREET, NEW HAVEN, CT

Prossima data di guadagno

Ultimi documenti SEC

TRVI's Discussions on Twitter

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-04-12	Iniziato	B. Riley Securities	Buy
2022-11-22	Iniziato	SVB Leerink	Outperform
2019-06-03	Iniziato	BMO Capital Markets	Outperform
2019-06-03	Iniziato	Needham	Buy
2019-06-03	Iniziato	SVB Leerink	Outperform
2019-06-03	Iniziato	Stifel	Buy

Mostra tutto

Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie

Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari

Trevi Therapeutics Inc Azioni (TRVI) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
GOOD JENNIFER L	President & CEO	Sep 09 '24	Option Exercise	1.43	1,840	2,631	215,153
GOOD JENNIFER L	President & CEO	Sep 06 '24	Sale	3.03	4,219	12,784	213,313
GOOD JENNIFER L	President & CEO	Sep 09 '24	Sale	3.04	1,840	5,587	213,313
GOOD JENNIFER L	President & CEO	Sep 05 '24	Option Exercise	1.43	40,277	57,596	253,590
GOOD JENNIFER L	President & CEO	Sep 04 '24	Option Exercise	1.43	10,981	15,703	224,294
GOOD JENNIFER L	President & CEO	Sep 03 '24	Option Exercise	1.43	3,863	5,524	217,176
GOOD JENNIFER L	President & CEO	Sep 05 '24	Sale	3.11	40,277	125,310	213,313
GOOD JENNIFER L	President & CEO	Sep 04 '24	Sale	3.02	10,981	33,205	213,313
GOOD JENNIFER L	President & CEO	Sep 03 '24	Sale	3.02	3,863	11,677	213,313

Trevi Therapeutics Inc (TRVI)

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie

Trevi Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.12) Per Share, Leerink Partnrs Forecasts (NASDAQ:TRVI) - MarketBeat

Trevi Therapeutics, Inc. Expected to Earn Q1 2025 Earnings of ($0.11) Per Share (NASDAQ:TRVI) - MarketBeat

Leerink Partnrs Upgrades Trevi Therapeutics (NASDAQ:TRVI) to "Strong-Buy" - MarketBeat

Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated by Analysts at Leerink Partners - Defense World

Trevi Therapeutics CEO sells over $18,000 in company stock - Investing.com

Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 4,219 Shares of Stock - MarketBeat

Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated at Leerink Partners - MarketBeat

Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock - sharewise

Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock - MSN

Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock - MarketBeat

Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $33,162.62 in Stock - MarketBeat

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - Citizentribune

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 – Company Announcement - Financial Times

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - StockTitan

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.80 Average Target Price from Analysts - Defense World

Trevi Therapeutics shares rise on bullish analyst initiation By Investing.com - Investing.com Canada

Raymond James initiates Trevi Therapeutics at Outperform, sees first-to-market opportunity for Haduvio - Investing.com Canada

Trevi Therapeutics (NASDAQ:TRVI) Research Coverage Started at Raymond James - MarketBeat

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated at Raymond James - Defense World

Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) Director Sells 4,555 Shares of Stock - MarketBeat

Trevi therapeutics director Meeker sells shares worth over $13,000 - Investing.com

Trevi Therapeutics to Participate in September Investor and Medical Conferences - PR Newswire

Trevi Therapeutics to Participate in September Investor and Medical Conferences - StockTitan

Trevi Therapeutics executive sells shares worth over $48,000 - Investing.com India

Trevi Therapeutics executive sells shares worth over $48,000 - Investing.com

Trevi Therapeutics executive sells shares worth over $48,000 By Investing.com - Investing.com UK

Trevi Therapeutics (NASDAQ:TRVI) Upgraded to "Strong-Buy" at EF Hutton Acquisition Co. I - MarketBeat

EF Hutton Acquisition Co. I Upgrades Trevi Therapeutics (NASDAQ:TRVI) to Strong-Buy - Defense World

Trevi Therapeutics Provides Business Updates - GuruFocus.com

EF Hutton initiates coverage on Trevi Therapeutics shares with Buy rating - Investing.com Canada

Price T Rowe Associates Inc. MD Purchases Shares of 13,561 Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Thomas Sciascia Sells 18,660 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock - Defense World

Trevi Therapeutics executive trades over $130k in company stock By Investing.com - Investing.com Australia

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Insider Thomas Sciascia Sells 18,660 Shares - MarketBeat

Trevi Therapeutics executive trades over $130k in company stock - Investing.com

Trevi Therapeutics executive trades over $130k in company stock By Investing.com - Investing.com UK

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Vanguard Group Inc. - Defense World

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Expected to Earn Q3 2024 Earnings of ($0.09) Per Share - MarketBeat

Trevi Therapeutics to Participate in Upcoming September Events - GuruFocus.com

B. Riley Research Analysts Decrease Earnings Estimates for Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Longview News-Journal

Trevi Therapeutics Announces the Initiation of its Phase 2b CORA - GuruFocus.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2024 Earnings Call Transcript - Insider Monkey

Earnings call: Trevi Therapeutics reports progress in chronic cough trials By Investing.com - Investing.com Australia

Earnings call: Trevi Therapeutics reports progress in chronic cough trials - Investing.com

Earnings call: Trevi Therapeutics reports progress in chronic cough trials By Investing.com - Investing.com Canada

Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript - Seeking Alpha

Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 - Quantisnow

TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024 - InvestorPlace

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance - Manchestertimes

Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Trevi Therapeutics Inc Azioni (TRVI) insider trading

Simile a TRVI